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Exposure  to estrogenic  compounds  has been  shown  to epigenetically  reprogram  the
prostate  and  may  contribute  to prostate  cancer.  The  goal  of  this  study  was to determine  the
effect  of  physiological  doses  of  estradiol  and bisphenol  A  (BPA)  on the  expression  of  his-
tone modifying  enzymes  (HMEs)  in  prostate  cancer.  Using  two human  prostate  cancer  cell
lines we  examined  the  expression  of  Set8, a histone  methyltransferase,  and  Sirt1,  a  histone
deacetylase,  after  exposure  to estrogen  or  BPA.  These  experiments  were  carried  out in  the
presence  of natural  hormones  to  understand  the  impact  of additional  exposure  to estrogen
or BPA  on HME  expression.  We  found  differential  expression  of  the  HMEs  in  the  different
models  and  between  the different  compounds.  Further,  we  determined  that  the  changes
in gene expression  occurred  via  estrogen  receptor  signaling  using  the  ER  antagonist,  ICI
182,780  (fulvestrant).  Interestingly  we  found  that  the  combination  of  ICI with estrogen  or
BPA greatly  affected  the  expression  of  Set8, even  when  the  hormone  alone  had no  effect.
This  study  demonstrates  that  the  effects  of estrogen  and  BPA  on  HME  expression  vary  and
that  the presence  of  both  the  estrogen  receptor  and  androgen  receptor  may  be  important
for  therapeutic  intervention.
©  2015  The  Authors.  Published  by  Elsevier  Ireland  Ltd. This  is  an  open  access  article  under
Y-NC-Nthe  CC  B
. Introduction
Prostate cancer affects one in six men  in the United
tates with more than 225,000 new cases each year [1].
here are only a few known risk factors for prostate can-
er, including age, family history, and ethnicity. Advances
n treatment have led to a ﬁve-year survival rate of 100% for
en  with local and regional disease [2]. For advanced dis-
ase, current therapies target the androgen receptor (AR)
r androgen production. Treatment causes the tumor to
egress, however relapse occurs and the resulting disease
s castration resistant prostate cancer (CRPC) [3]. For this
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advanced stage, there are few treatment options available
and the disease eventually causes lethality.
Environmental exposures have been demonstrated to
contribute to disease development and progression [4],
including prostate cancer [5]. Speciﬁcally, bisphenol A
(BPA) is a synthetic estrogen widely produced in the United
States [6] that has been shown to impact the develop-
ment of the nervous [7,8] and reproductive systems [9]. The
prostate gland in particular has been found to be suscep-
tible to both estrogen and BPA exposure in animal models
and this exposure impacts disease development later in life
([10,11]). The mechanism of action does not appear to be
mutagenic but rather evidence indicates that in both breast
and prostate tissue BPA alters the epigenome [12,13].Tang et al. [11] studied the impact of estrogen and BPA
on the prostate methylome and found differential meth-
ylation patterns for multiple genes throughout the life
of exposed animals. This study demonstrated that early
cess article under the CC BY-NC-ND license (http://creativecommons.org/
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exposure can cause lasting epigenetic changes to the
prostate methylome. The goal of the present study was
to analyze the expression of histone modifying enzymes
(HMEs) that might be altered after exposure to estrogen
or BPA in human prostate cancer. We  analyzed the expres-
sion of two HMEs, SET8 and SIRT1, that have previously
been shown to be involved in both estrogen signaling and
cancer.
SET8 is the only enzyme to found to monomethylate his-
tone H4 lysine 20 (H4K20me1). In breast cancer, it has been
shown to be an essential co-activator of estrogen recep-
tor alpha (ER) mediated transcription [14]. Furthermore,
SET8 plays a role in the epithelial to mesenchyme (EMT)
transition in breast cancer by regulating both E and N cad-
herin [15,16]. In prostate cancer, SET8 has been found to be
enriched at the AR target gene PSA and loss of SET8 resulted
in a loss of PSA expression. Additionally, SET8 was  found to
be necessary for AR induced proliferation of prostate cancer
cells [17].
SIRT1 is a histone deacetylase (HDAC) that is involved
in regulating ER transcription in breast cancer [18].
Estrogen has been shown to increase the expression of
SIRT1 in breast cancer cells and this required the ER. Fur-
thermore, depletion of SIRT1 decreased growth of breast
cancer cells [19]. SIRT1 expression is increased in human
prostate cancer [20] and also plays a role in EMT  in
prostate cancer [21]. Speciﬁcally, SIRT1 overexpression
induced EMT  in an epithelial prostate model and knock
down of SIRT1 restored cell adhesion in prostate cancer
cells. Similar to SET8, this was mediated by regulation of
E-cadherin. In addition, Sirt1 was decreased after expo-
sure to genistein, a phytoestrogen, in human prostate
cancer cells [22], and Taken together, these studies indi-
cate that Set8 and Sirt1 play important roles in cancer
and that their expression may  be regulated by estrogenic
compounds.
Many studies have examined gene expression in
response to estrogenic compounds. Typically in these stud-
ies, cells are maintained in full media while experiments
are carried out after hormone deprivation [23–25]. This
approach is utilized since it eliminates confounding issues,
such as the presence of other steroid hormones. One caveat
to this approach is that it is not representative of physio-
logical conditions, including androgen depletion, as there
are still natural and synthetic estrogens present in the
system. To understand what might be occurring under
more physiological relevant conditions, we analyzed the
expression of these genes in the presence of physiologi-
cal hormone levels rather than after hormone deprivation.
Using two different models of human prostate cancer, we
found signiﬁcant changes in the expression of Set8 but few
in Sirt1. We  also found that the changes in Set8 expres-
sion were dependent on ER as they were reversed by an
ER antagonist. Lastly, estrogen and BPA did not elicit the
same outcomes with regards to Set8 and Sirt1 expression.
Taken together this data demonstrates that exposure to
estrogenic compounds affects the expression of HMEs dif-
ferently. Furthermore, there are distinct changes in the
different models examined indicating that the regula-
tion of these enzymes may  change in different disease
states.orts 2 (2015) 817–823
2. Materials and methods
2.1. Cell culture and treatment
The LNCaP and PC3 cell lines were a kind gift
from Dr. Shuk-Mei Ho (University of Cincinnati, Cincin-
nati, OH). The LNCaP cell line was  maintained in
RPMI/1640 medium (Life Technologies) supplemented
with 2 mM/L  l-glutamine and 1 mM sodium pyruvate
(Gibco). PC3 cells were maintained in DMEM/F12 medium
(ATCC). Both medium were supplemented with 10% heat
inactivated fetal bovine serum (Atlanta Biologicals) and
100 units/mL of penicillin–streptomycin (Life Technolo-
gies). Cells were cultured at 37 ◦C in a 5% CO2 heated
incubator.
17-Estradiol, bisphenol A, and ICI 182,780 (Fulves-
trant) were purchased from Sigma–Aldrich. Cells were
treated with 1, 5, or 10 nM estradiol or 10, 25, or 50 nM
bisphenol A for 24 h. Where indicated, the ER inhibitor ICI
was  added at 10 M at the same time as the estradiol or
BPA. All treatments were for 24 h and 95% ethanol (0.1%)
was  used as the vehicle control.
2.2. RNA isolation and PCR
LNCaP and PC3 cells were seeded in six well dishes.
After 48 h the cells were treated with either 17-estradiol
or BPA with or without ICI. Total RNA was isolated via
Trizol reagent (Life Technologies) as recommended by
the manufacturer. Reverse transcription was  done using
the High Capacity RNA to cDNA kit (Life Technologies)
as recommended by the manufacturer. PCR was  per-
formed to analyze expression levels of Sirt1, Set8, and
GAPDH. The expression level of each gene was normal-
ized to the expression of GAPDH.  GAPDH was  chosen
as the house-keeping gene because its expression did
not change in response to estrogen or BPA. The rela-
tive expression was analyzed using Image J software. The
experiments were repeated with three individual sets of
samples.
2.3. Statistical analysis
Data were expressed as mean ± SD. Bonferroni post
hoc test (correction test) was performed following ANOVA
(Prism v4.0, GraphPad, CA) for multiple comparisons to
determine the statistical signiﬁcance.
3. Results
3.1. Differential expression of Set8 and Sirt1 in response
to estrogen and BPA in LNCaP cells
To understand the effects of estrogen and BPA on the
expression of HME  genes in human prostate cancer we
ﬁrst utilized the LNCaP cell model. These cells are depend-
ent upon androgens for growth, express a mutant AR and
express ER.  Previous experiments analyzing the effects
of estrogen or BPA have been performed under conditions
of hormone depletion. To understand changes that occur
under physiologically relevant conditions, the treatments
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ere performed in complete media (FBS) rather than in
ormone depleted media (CSS). Three physiologically rele-
ant doses for both estrogen and BPA were chosen to mimic
he range of human exposure. The samples were collected
4 later since this time point has been previously shown to
llow sufﬁcient time for transcription following hormone
reatment [26].
The effects of E2 and BPA on Set8 and Sirt1 expres-
ion in LNCaP cells were examined 24 h after exposure.
he expression of Set8 was unaffected by estrogen treat-
ent (Fig. 1A left panel). In contrast, estrogen (5 nM)
nduced a 1.4-fold increase in Sirt1 expression (Fig. 1A).
ext we examined the effect of BPA on gene expression
n LNCaP cells. Set8 expression showed a trend of increased
xpression following BPA exposure, with an average of 1.7-
old increase (25 nM), approaching statistical signiﬁcance.
here was however no signiﬁcant change in the expression
f Sirt1 (Fig. 1B). This was slightly different than the effect
f estrogen implying that different exposures to estrogenic
ompounds have distinct impacts on gene expression. Fur-
hermore, these experiments show that in the presence
ig. 1. Effect of estrogen or BPA on gene expression of HMEs in LNCaP cells. (A)
nd  the expression of Set8 (left panel) or Sirt1 (right panel) was  analyzed. (B) LN
xpression of Set8 (left panel) or Sirt1 (right panel) was  analyzed. Image J was used
o  GAPDH from the same sample. Results are from three independent experimentorts 2 (2015) 817–823 819
of natural levels of hormones, BPA or additional estrogen
exposure can signiﬁcantly change the expression of HMEs.
3.2. Differential expression of Set8 and Sirt1 in response
to estrogen and BPA in PC3 cells
There are dramatic changes in prostate cancer as the
disease progresses. Initially it is androgen dependent but
progresses to CRPC. To aid our understanding of the differ-
ences between androgen dependent and CRPC we  analyzed
the expression of Set8 and Sirt1 in response to estrogen and
BPA in PC3 cells, a castration resistant model. PC3 cells
lack the AR but express both ERs. Exposure to estrogen
caused a 30% reduction in Set8 expression at all three doses
but had no effect on Srit1 expression (Fig. 2A). Similarly,
BPA also caused a 20% reduction in Set8 expression but
only at the 25 nM dose and had no effect on Sirt1 expres-
sion in PC3 cells (Fig. 2B). While both estrogen and BPA
caused a decrease in Set8, this is different from the results in
LNCaP cells, demonstrating different outcomes in different
prostate cancer models.
 LNCaP cells were treated with the indicated doses of estrogen for 24 h
Cap cells were treated with the indicated doses of BPA for 24 h and the
 to quantitate the results and the expression of each gene was  normalized
s (*p < 0.05).
820 K. Burton et al. / Toxicology Reports 2 (2015) 817–823
. (A) PC3
 cells we
uantita
(*p < 0.05Fig. 2. Effect of estrogen or BPA on gene expression of HMEs in PC3 cells
expression of Set8 (left panel) or Sirt1 (right panel) was  analyzed. (B) PC3
Set8  (left panel) or Sirt1 (right panel) was  analyzed. Image J was  used to q
from  the same sample. Results are from three independent experiments 
3.3. Differential expression of Set8 and Sirt1 by estrogen
and BPA is dependent on ER signaling
To determine if estrogen and BPA are altering the
expression of Set8 and Sirt1 through ER signaling, we
utilized the ER antagonist, ICI 182,780 (fulvestrant). The
treatments were carried out as described above in the pres-
ence of estrogen or BPA in combination with ICI.
As expected, in LNCaP cells the expression of Sirt1 was
reversed in the presence of ICI (Fig. 3A). Interestingly, even
though neither estrogen nor ICI alone affected the expres-
sion of Set8, we found that the combination of estrogen and
ICI decreased Set8 expression. Speciﬁcally the combination
resulted in approximately a 30% decrease in Set8 expres-
sion at all three doses of estrogen in combination with ICI,
which was signiﬁcant at the 5 nM dose (Fig. 3B left panel).
This unexpected result implies that even though estrogen
alone did not impact regulation, when there is a certain
amount of estrogen present and the estrogen receptor is
inhibited, gene expression may  be affected.
Next we examined if the increased expression of Set8
by BPA was mediated via ER signaling by treating LNCaP
cells with BPA and ICI. BPA increased Set8 expression more
than 1.5-fold at the 10 and 25 nM doses and this induction
was reversed by ICI. Even though there was no induction
of Set8 at the 50 nM BPA dose, the combination of BPA and cells were treated with the indicated doses of estrogen for 24 h and the
re treated with the indicated doses of BPA for 24 h and the expression of
te the results and the expression of each gene was  normalized to GAPDH
).
ICI signiﬁcantly reduced the expression of Set8 at all three
doses (Fig. 3B right panel). The greatest reduction occurred
at the 25 nM dose, decreasing Set8 expression by 55% com-
pared to the untreated (vehicle) control. These data show
that the combination of an ER antagonist and an estrogen
(E2 or BPA) alter the expression of Set8 even when there
was  no observed effect with the hormone.
The same experiments were carried out in PC3 cells to
determine if the changes in gene expression were mediated
by ER signaling. Treatment with ICI reversed the effect of
estrogen on Set8 expression clearly demonstrating that ER
signaling is the mechanism by which estrogen regulates
Set8 expression (Fig. 4A). BPA alone induced a decrease
in Set8 expression at 25 nM.  Treatment with ICI reversed
this effect (average expression was 1.1), although it did not
reach statistical signiﬁcance (Fig. 4B). Taken together, these
data indicate that both estrogen and BPA are regulating
gene expression in prostate cancer via ER signaling.
4. Discussion
We  set out to determine if estrogen and the endocrine
disruptor, BPA, affect the expression of HMEs in human
prostate cancer in the presence of physiological hormones.
We  found that both estrogen and BPA regulate the expres-
sion of Set8 and Sirt1 and that there are distinct effects with
K. Burton et al. / Toxicology Reports 2 (2015) 817–823 821
Fig. 3. Estrogen and BPA signal through the estrogen receptor to alter Set8 expression in LNCaP cells. (A) LNCaP cells were treated with estrogen alone or
in  presence of ICI (10 M)  for 24 h and Sirt1 expression was  analyzed. (B) LNCaP cells were treated with estrogen (left panel) or BPA (right panel) alone or
in  the presence of ICI (10 M)  for 24 h and Set8 expression was  analyzed. Image J was  used to quantitate the results and the expression was normalized to
GAPDH  from the same sample. Results are from three independent experiments (*p<.05).
Fig. 4. Estrogen and BPA signal through the estrogen receptor to alter Set8 expression in PC3 cells. (A) PC3 cells were treated with estrogen alone or in the
presence of ICI (10 M)  for 24 h and Set8 expression was analyzed. (B) PC3 cells were treated with BPA alone or in the presence of ICI (10 M)  for 24 h and
Set8  expression was  analyzed. Image J was used to quantitate the results and the expression was normalized to GAPDH from the same sample. Results are
from  three independent experiments (*p < .05).
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each compound. Furthermore, we found that the effects
exerted by these compounds differ between the two mod-
els of human prostate cancer analyzed. Additionally, we
showed that the regulation of gene expression was  via ER,
as the effects were reversed in all cases by the ER antagonist
ICI.
Previous studies have looked at the effect these com-
pounds have on the rat prostate methylome and the
enzymes that modify the methylome. It is understood from
these studies that BPA alters the prostate methylome in
animal models. To further our understanding of the dis-
ease state we sought to determine if estrogen and BPA
altered HMEs in human prostate cancer since histone mod-
iﬁcations are another key epigenetic mechanism altered
in cancer. Additionally, drugs targeting HMEs are more
readily tolerated by patients than compounds that impact
DNA methylation, therefore identifying which enzymes are
altered by endocrine disruptors may  be informative for
therapeutic intervention.
Both Set8 and Sirt1 have been found to play a role in
EMT and so understanding how exposure to endocrine
disruptors affects their expression could aid in under-
standing disease progression. While we identiﬁed very few
changes in Sirt1 expression, we found that Set8 was altered
under multiple conditions and that its regulation differed
between the two models of prostate cancer. While estro-
gen had no effect on Set8 in LNCaP cells, it reduced the
expression of Set8 in PC3 cells, demonstrating that the
molecular status of prostate cancer inﬂuences the outcome
of Set8 expression. Unlike the results with estrogen, BPA
induced an increase in Set8 expression in LNCaP cells but
only reduced the expression of Set8 at one dose in PC3
cells. In both models then, BPA had a distinct outcome with
regards to Set8 expression.
Interestingly we found that the combination of estro-
gen or BPA with ICI decreased the expression of Set8 in
LNCaP cells. It is important to note that ICI alone had no
effect on Set8 expression, but only reduced Set8 expres-
sion when in combination with an estrogenic compound.
The fact that this only occurred in LNCaP cells and not PC3
cells may  be explained by studies showing that ICI inhibits
prostate cancer progression both by down regulating the
androgen receptor (AR) [27] and through inhibition of ER
[28]. LNCaP cells express AR and only ER,  while PC3 cells
are AR negative and express both ERs [29]. This has rele-
vance for treatment because a decrease in Set8 expression
could result in an inhibition of EMT  in patients. However,
in the PC3 cells, ICI in combination with estrogen or BPA
restored the expression of Set8, which may  or may  not pro-
mote EMT  and therefore have a negative clinical outcome.
There have been recent investigations into the use of ICI as
a treatment for CRPC with conﬂicting outcomes. In a small
clinical study of CRPC patients, ICI decreased PSA levels
without any reports of toxicity when a loading dose was
given in the ﬁrst month of treatment [30], however there
was no discernible affect in a phase II clinical trial [31]. The
utility of ICI as a therapy for prostate cancer, therefore, may
in part depend on both the AR and ER status of the tumor.
There has been some investigation into the role of
GPR30 in prostate cancer and its potential as a therapeu-
tic target. GPR30 is an orphan G-protein coupled receptororts 2 (2015) 817–823
with high afﬁnity for estrogen. It rapidly activates Erk1/2
signaling upon stimulation [32]. It is possible that GPR30
is playing a role in response to either estrogen or BPA,
however, given that ICI, the estrogen receptor antagonist,
reversed the effects of both estrogen and BPA, GPR30 most
likely has a minimal role in this study. Additionally, ICI has
been found to be an agonist for GPR30 [33] and we did not
observe and signiﬁcant changes in gene expression when
the cells were treated with ICI alone. Taken together, our
data indicates that GPR30 is not the main mechanism by
which estrogen or BPA regulate SET8 or SIRT1.
Many studies have been performed to show that HMEs
play a role in estrogen signaling. We  set out not only
to determine if estrogen and BPA regulate the expres-
sion of HMEs but whether they do so in the presence
of physiological hormones. This is an important distinc-
tion as it more closely resembles the disease state because
even with androgen deprivation, there is still a plethora of
hormones, including natural and synthetic estrogens that
could impact gene expression. It would be of interest to
examine the effects of estrogen and BPA on SET8 and SIRT1
enzyme activity as our study solely analyze gene expres-
sion. Additionally, investigating what occurs at later time
points as well as with prolonged exposure to BPA would
be of interest as humans are constantly exposed to BPA.
Lastly, understanding how current therapies are impacted
by exposure to endocrine disruptors like BPA could inform
treatment.
5. Conclusion
It is clear from our study that with a very short expo-
sure time (24 h), changes in HME  gene expression were
observed in response to E2 and BPA. Perhaps most interest-
ingly, we  found that the combination of an ER antagonist
and an estrogenic compound had distinct effects on HME
expression than either compound alone. This is relevant as
estrogens and estrogen receptor inhibitors are being inves-
tigated, alone or as adjuvants, as potential therapies for
prostate cancer.
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